January 01, 2020 article Head and Neck Cancer New England Journal of Medicine DOI: 10.1056/nejmra1715715 OpenAlex Authors 0 Author list not loaded yet. Cited by 9 stored of 2,158 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer 2025 Journal for ImmunoTherapy of Cancer article Medicine Head and Neck Cancer Studies Open access 6 citations Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer 2025 npj Precision Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access 11 citations UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial 2025 Med article Medicine Head and Neck Cancer Studies Open access 7 citations Inflammatory signature and restriction of adaptive immunity are associated with unfavorable outcomes on immune checkpoint blockade in patients with advanced head and neck squamous cell carcinoma 2024 medRxiv preprint Medicine Cancer Immunotherapy and Biomarkers Open access 0 citations UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial 2024 medRxiv preprint Medicine Cancer Immunotherapy and Biomarkers Open access 1 citations Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial 2024 Frontiers in Oncology article Medicine Cancer Immunotherapy and Biomarkers Open access 11 citations Real-time detection of bone-invasive oral cancer with laser-induced breakdown spectroscopy: A proof-of-principle study 2023 Oral Oncology article Engineering Laser-induced spectroscopy and plasma 22 citations Impact of quality certification of multidisciplinary head and neck tumor centers 2021 Cost Effectiveness and Resource Allocation article Health Professions Healthcare Quality and Management Open access 13 citations Management of the clinically N0 neck in early-stage oral squamous cell carcinoma (OSCC). An EACMFS position paper 2020 Journal of Cranio-Maxillofacial Surgery article Medicine Head and Neck Cancer Studies 68 citations 9 results References 0